Eli Lilly: As donanemab filing approaches, execs 'even more confident' in data package

Kyle Blankenship

Eli Lilly had a strong Q2, but unsurprisingly analysts don’t want to talk much about drugs already approved — their eyes are set firmly on Alzheimer’ …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Eli Lilly: As donanemab filing approaches, execs 'even more confident' in data package

Kyle Blankenship

Sign up to read this article for free.

Jazz wins approval for bispecific in biliary tract cancer

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

Are programs with compounded GLP-1s safe for your population?

Eli Lil­ly: As do­nanemab fil­ing ap­proach­es, ex­ecs 'even more con­fi­den­t' in da­ta pack­age

Kyle Blankenship

Sign up to read this article for free.

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Eli Lilly: As donanemab filing approaches, execs 'even more confident' in data package

Jazz wins approval for bispecific in biliary tract cancer

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

Are programs with compounded GLP-1s safe for your population?